Article Figures & Data
Figures
- FIGURE 1.
68Ga-DOTANOC PET/CT maximum-intensity-projection (A) and transaxial images (B and C) of patient with G2 pNET (A and B) and liver metastasis (A and C). Measured SUVmax was 56. Patient had stable disease at follow-up.
- FIGURE 2.
(A) 68Ga-DOTANOC PET/CT maximum-intensity-projection images of patient who previously underwent surgery for pNET and presented with liver metastasis having SUVmax of 6.7 (solid arrow). (B) Patient showed disease progression at follow-up. Dashed arrow indicates accessory spleen.
- FIGURE 3.
PFS in 43 patients with well-differentiated pNET (G1 and G2) according to Ki-67 (A) (dashed line = Ki-67 > 5%; solid line = Ki-67 < 5%; P = 0.005), SUVmax (B) (dashed line = SUVmax < 37.8; solid line = SUVmax > 38; P = 0.002), and treatment (C) (dashed line = medical therapy; solid line = medical therapy plus PRRT; P = 0.014).
Tables
SUVmax Patient characteristic No. of patients Median IQR P Sex Male 22 45.9 36.3–58.2 0.875 Female 21 37.8 35.7–69.3 Syndrome Yes 8 33.9 19.8–95.6 1.000 No 35 45.5 38.6–57.4 Stage IIIB 7 34.3 25.2–62.2 0.687 IV 36 48.9 39.9–62.1 2010 WHO classification NET G1 14 57.7 42.4–79.3 0.092 NET G2 29 36.2 33.2–55.7 Ki-67 ≤5% 22 53.3 42.5–68.6 0.132 >5% 21 36.0 29.1–58.5 Follow-up at 24 mo Stable disease 18 49.8 44.9–78.8 0.022 Progressive disease 20 33.4 26.1–52.4 - TABLE 2
Risk Factors for Disease Progression During Follow-up at Univariate and Multivariate Analysis
Univariate Multivariate Patient characteristic HR 95% confidence interval P HR 95% confidence interval P Sex (male vs. female)* 0.80 0.40–1.61 0.532 — — — Syndrome (no vs. yes)* 1.86 0.71–4.89 0.205 — — — Stage IV vs. IIIB* 1.87 0.71–4.94 0.209 3.31 1.16–9.47 0.026 NET G2 vs. NET G1 1.94 0.86–4.35 0.109 Ki-67 (>5% vs. ≤5%)* 2.89 1.31–6.34 0.009 3.24 1.34–7.84 0.009 Ki-67 (continuous) 1.09 1.02–1.17 0.009 SUVmax (≤37.8 vs. ≥38.0)* 3.09 1.46–6.57 0.003 2.37 1.03–5.47 0.043 Therapy (medical vs. PRRT)* 2.36 1.16–4.80 0.018 2.70 1.21–6.03 0.015 ↵* Variables in multivariate analysis.
Jump to section
Related Articles
Cited By...
- Semiautomatic Tumor Delineation for Evaluation of 64Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume
- Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
- 64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms